How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma

Review

Konstantinos Arvanitakis 1,2 , Theocharis Koufakis 3 , Kalliopi Kotsa 3 and Georgios Germanidis 1,2

1 First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki,
54636 Thessaloniki, Greece
2 Basic and Translational Research Unit (BTRU) of Special Unit for Biomedical Research and Education
(SUBRE), School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
3 Division of Endocrinology and Metabolism and Diabetes Centre, First Department of Internal Medicine,
AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece

Δείτε ΕΔΩ το άρθρο